Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Zynerba Pharma CS (ZYNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 250,823
  • Shares Outstanding, K 13,250
  • Annual Sales, $ 10 K
  • Annual Income, $ -23,390 K
  • 36-Month Beta 5.17
  • Price/Sales 36,191.43
  • Price/Cash Flow 0.00
  • Price/Book 3.26

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.27 +13.83%
on 06/12/17
20.73 -10.66%
on 06/27/17
-0.48 (-2.53%)
since 05/26/17
3-Month
16.27 +13.83%
on 06/12/17
25.95 -28.63%
on 04/13/17
-1.50 (-7.49%)
since 03/28/17
52-Week
6.31 +193.50%
on 06/29/16
25.95 -28.63%
on 04/13/17
+11.95 (+181.89%)
since 06/28/16

Most Recent Stories

More News
Zynerba Pharmaceuticals Added to the Russell 3000(R) Index

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today...

ZYNE : 18.52 (-2.17%)
Zynerba Pharmaceuticals Initiates ZYN001 Phase 1 Clinical Program

Phase 1 results will inform potential Phase 2 studies in patients with fibromyalgia and neuropathic pain, planned to start in 2H17

ZYNE : 18.52 (-2.17%)
Legal Cannabis and CBD Markets are Projected to Grow

According to a research report published by Arcview Market Research, the growth of the legal cannabis market is projected to reaccelerate beginning in 2018. Adult use sales would ramp up in Canada, California,...

CBDS : 4.3000 (-0.92%)
AXIM : 10.4900 (-0.57%)
STVFD : 0.6400 (+4.92%)
CIIX : 0.9400 (-4.08%)
VBIO : 2.1650 (-3.35%)
ZYNE : 18.52 (-2.17%)
Zynerba Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today...

ZYNE : 18.52 (-2.17%)
How These Generic Drugs Stocks are Faring? -- MYOS RENS Technology, Akari Therapeutics, Flexion Therapeutics, and Zynerba Pharma

On Thursday, May 18, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Five out of nine sectors ended Thursday's trading session in bullish...

AKTX : 5.04 (+0.60%)
MYOS : 1.77 (-0.63%)
FLXN : 21.56 (+3.50%)
ZYNE : 18.52 (-2.17%)
Zynerba Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Highlights

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today...

ZYNE : 18.52 (-2.17%)
The Creation of Jobs in the Legal Cannabis Market

According to a research by Arcview Market Research, retail sales taxes in state-sanctioned cannabis markets totaled more than $500 million in 2016 in Colorado, Washington, Oregon, and $836 million since...

ACAN : 2.5000 (-5.80%)
CARA : 26.95 (+2.01%)
CRBP : 6.25 (+1.63%)
INSY : 13.10 (+5.05%)
ZYNE : 18.52 (-2.17%)
SYT : 92.66 (+0.06%)
The Legal Cannabis Market Expected to Witness Wider Adoption

According to a research report by Market Research Future, the Cannabis market in North America was valued at over USD 3.5 billion for the full year of 2015. Of that, the United States being the largest...

CARA : 26.95 (+2.01%)
AXIM : 10.4900 (-0.57%)
STVFD : 0.6400 (+4.92%)
CIIX : 0.9400 (-4.08%)
VBIO : 2.1650 (-3.35%)
ZYNE : 18.52 (-2.17%)
Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options

Options traders are pricing in a big move for Zynerba Pharmaceuticals (ZYNE) shares as it has huge implied volatility.

ZYNE : 18.52 (-2.17%)
How These Generic Drugs Stocks are Faring? -- Zynerba Pharma, Patheon, SCYNEXIS, and Flexion Therapeutics

Stock-Callers.com today observes the following Generic Drugs equities: Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Patheon N.V. (NYSE: PTHN), SCYNEXIS Inc. (NASDAQ: SCYX), and Flexion Therapeutics Inc....

SCYX : 1.91 (+1.06%)
ZYNE : 18.52 (-2.17%)
FLXN : 21.56 (+3.50%)
PTHN : 34.85 (+0.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal...

See More

Support & Resistance

2nd Resistance Point 19.87
1st Resistance Point 19.19
Last Price 18.52
1st Support Level 17.92
2nd Support Level 17.33

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.